On Wednesday December 5, 2018, UACT, along with KEI, Social Security Works, Health GAP, Public Citizen, Dr. Ophira Ginsburg, and James Love, submitted joint comments in response to a proposed exclusive license for patents on CAR T technology for the treatment of cancers. The Federal Register notice (83 FR 58262) “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like Tyrosine Kinase 3 (FLT3) Expressing Cancers,” outlined the National Institutes of Health’s intent to grant an exclusive license on these technologies to ElevateBio, a company whose leadership includes the investors behind recent budget-breaking treatments,Read More →

On October 31, 2018 UACT sent the following letter to President Trump regarding his statements about protections for pre-existing conditions in the lead up to the midterm elections. A PDF of the letter is available here.   Union for Affordable Cancer Treatment 1621 Connecticut Avenue NW Suite 500 Washington, DC 20009 Tel.: 202.332.2670 www.uact.org October 31, 2018 President Donald Trump The White House 1600 Pennsylvania Avenue NW Washington, DC 20500 President Trump, I am writing on behalf of the Union for Affordable Cancer Treatment (UACT) to say that we are appalled that you are now claiming that the Republican party will protect patients with pre-existingRead More →

The following are comments by the Union for Affordable Cancer Treatment (UACT) on the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, in response to the notice published in the Federal Register, 83 FR 22692. Element II.B. of the notice asks, “What policies should the U.S. government pursue in order to protect IP rights and address concerns around compulsory licensing” in OECD countries, which “are not paying an appropriate share of the necessary research and development to bring innovative drugs to the market and are instead freeriding off U.S. consumers and taxpayers.” 1. UACT rejects the premise put forth by the Blueprint thatRead More →

The Union for Affordable Cancer Treatment (UACT) welcomes the news that a Russian court has approved a compulsory license for patents held by Celgene for the cancer drug lenalidomide, marketed in many countries under the trade name Revlimid. Compulsory licenses on patents can promote health and protect the interests of cancer patients when there is excessive pricing and other abuses of a legal monopoly. Since entering the market, Revlimid has generated more than $46 billion in sales for Celgene, including $2.3 billion in the first three months of 2018. In the United States, Celgene still claims the drug is protected by 26 patented inventions andRead More →

On June 8, 2018 Miroslav Lajčák (Slovak Republic), President of the United Nations General Assembly circulated the zero-draft of the Political Declaration of the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases (NCDs). Italy (Ambassador Sebastiano Cardi) and Uruguay (Ambassador Elbio Rosselli) have served as the co-facilitators of this negotiation. The zero draft is the initial negotiating text framing the UN’s response to addressing the public health crisis of NCDs globally. Analogous to the high-level process for tuberculosis, this text will be the subject of intense negotiations with countries adding and deleting text over the next four weeks.Read More →